BTK News

News

Ibrutinib Maintenance Demonstrates Feasibility Post-Induction Therapy Among Patients With Previously Treated MCL

11/28/2023

BTK inhibitor ibrutinib maintenance following induction chemo-immunotherapy was feasible and demonstrated manageable safety among certain patients with treatment-naive mantle cell lymphoma.

BTK inhibitor ibrutinib...

11/28/2023

Oncology

News

Obinutuzumab, Ibrutinib, and Venetoclax Combination Demonstrates Sustained Remissions Among Patients With High-Risk CLL

11/03/2023

Jordan Kadish ;

A regimen consisting of obinutuzumab, ibrutinib, and venetoclax demonstrated promising sustained remission among patients with high-risk chronic lymphocytic leukemia with del(17p) and/or TP53 mutation, according to a final analysis of the...

A regimen consisting of...

11/03/2023

Oncology

News

BTK Inhibitor Zanubrutinib vs Ibrutinib Among Patients With Waldenström Macroglobulinemia

09/27/2023

Jordan Kadish ;

BTK inhibitor zanubrutinib exhibited similar efficacy and improved safety compared to ibrutinib among patients with Waldenström macroglobulinemia, according to a final analysis of the phase 3 ASPEN trial.

BTK inhibitor zanubrutinib...

09/27/2023

Oncology

News

Ibrutinib Plus Rituximab Demonstrates Efficacy as Second-Line Treatment for Patients With CLL and R/R AIHA/PRCA

09/21/2023

Jordan Kadish ;

A phase 2 trial found that ibrutinib plus rituximab demonstrated efficacy among patients with CLL and steroid refractory autoimmune cytopenias such as autoimmune hemolytic anemia and pure red cell aplasia.

A phase 2 trial found that...

09/21/2023

Oncology

News

BTK Inhibitor Ibrutinib Plus Venetoclax Improved PFS vs Chlorambucil and Obinutuzumab Regimen Among Older Patients With Previously Untreated CLL

09/01/2023

Jordan Kadish ;

BTK inhibitor ibrutinib plus BCL-2 inhibitor venetoclax improved progression-free survival among older or comorbid patients with previously untreated chronic lymphocytic leukemia vs treatment with chlorambucil and obinutuzumab.

BTK inhibitor ibrutinib plus...

09/01/2023

Oncology

News

Patients With BCL2/MYC High-Expressing Non-GCB DLBCL May Be Preferentially Responsive to BTK Inhibitor Ibrutinib Plus R-CHOP Regimen

08/02/2023

Jordan Kadish ;

Patients with high BCL2/MYC coexpression non-GCB DLBCL may demonstrate improved event-free survival from the addition of BTK inhibitor ibrutinib to R-CHOP treatment, according to an analysis of the phase 3 PHOENIX trial.

Patients with high BCL2/MYC...

08/02/2023

Oncology

News

Nivolumab Plus BTK Inhibitor Ibrutinib Demonstrates Activity, Safety Among Patients With DLBCL Richter Transformation

07/17/2023

Jordan Kadish ;

According to a phase 2 trial, the combination of nivolumab and BTK inhibitor ibrutinib is an active and safe regimen among patients with diffuse large B-cell lymphoma Richter transformation.

According to a phase 2 trial,...

07/17/2023

Oncology

News

Clinical Outcomes After BTK Inhibitor and B-Cell Lymphoma 2 Inhibitor Treatment Among Patients With CLL

06/08/2023

Jordan Kadish ;

The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...

The real-world response rates...

06/08/2023

Oncology

News

BTK Inhibitor Acalabrutinib With or Without Obinutuzumab Demonstrated Improved Quality-Adjusted Survival Time Among Patients With Treatment-Naive CLL

06/06/2023

Jordan Kadish ;

A phase 3 trial indicated that acalabrutinib with or without obinutuzumab resulted in improved quality-adjusted time without symptoms and toxicity vs chlorambucil plus obinutuzumab for patients with previously untreated CLL.

A phase 3 trial indicated that...

06/06/2023

Oncology

News

Ibrutinib Demonstrated Efficacy Among Patients With Heavily Pretreated R/R MCL

05/01/2023

Jordan Kadish ;

Findings from a multicenter real-world retrospective analysis indicate that BTK inhibitor ibrutinib demonstrated good efficacy among patients with heavily pretreated R/R mantle cell lymphoma.

Findings from a multicenter...

05/01/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology